Safety and Outcome Measures of Pain Medications Used in Children and Pregnant Women (R01, R03, R21)

Funding Agency:
National Institutes of Health

The purpose of this funding opportunity announcement (FOA) is to (1) promote preclinical, translational, clinical and epidemiological research in pain medications use in children or in pregnant women to fill knowledge gaps in safe use of the pain medications in these special populations; and (2) develop effective instruments or approaches to assess and evaluate maternal and child outcomes of pain medication treatments.

There is a need for data on pain medications used in children and pregnant women to be shared and made available to the scientific community for future studies and to encourage replication of findings and meeting the goal of further advancing research in this area.

Although this funding opportunity uses the R01 grant mechanism, it runs in parallel with two program announcements of identical scientific scope: PA-18-043, for exploratory/developmental (R21) grants, and PA-18-044, for R03 small grants.


  • R01 Due Dates: Feb. 5, Jun. 5, Oct. 5
  • R03 and R21 Due Dates: Feb. 16, Jun. 16, Oct. 16
  • AIDS Due Dates: Jan. 7, May 7, Sep. 7

PA-18-038 Expiration Date January 8, 2020




Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

October 5, 2019